Main > ONCOLOGY (**) > Leukemia>Lymphocytic>Chronic *** > Treatment > USA. A. Ibrutinib+ObinutuzuMAb
USA. A. Ibrutinib+ObinutuzuMAb's subsections
(*) USA Approval Date: 2019. 01.28.
Company
Ibrutinib TradeMark
Ibrutinib TradeMark Web-Site
ObinutuzuMAb TradeMark
ObinutuzuMAb TradeMark Web-Site
USA. A. Ibrutinib+ObinutuzuMAb's products
This section has no products